Transgene Management
Management criteria checks 1/4
Transgene's CEO is Alessandro Riva, appointed in Jun 2023, has a tenure of 1.92 years. total yearly compensation is €840.00K, comprised of 71.4% salary and 28.6% bonuses, including company stock and options. directly owns 0.022% of the company’s shares, worth €17.77K. The average tenure of the management team and the board of directors is 1.1 years and 5.3 years respectively.
Key information
Alessandro Riva
Chief executive officer
€840.0k
Total compensation
| CEO salary percentage | 71.4% |
| CEO tenure | 1.9yrs |
| CEO ownership | 0.02% |
| Management average tenure | 1.1yrs |
| Board average tenure | 5.3yrs |
Recent management updates
Recent updates
TG4050 Trial And Pipeline Developments Will Transform Cancer Vaccines
Apr 07 Progress in TG4050 trials could establish Transgene as a leader in cancer vaccines, boosting reputation and revenue opportunities.Is Transgene (EPA:TNG) Using Too Much Debt?
Jun 15
Downgrade: Here's How Analysts See Transgene SA (EPA:TNG) Performing In The Near Term
Mar 21Transgene SA (EPA:TNG) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Mar 19Does Transgene (EPA:TNG) Have A Healthy Balance Sheet?
Mar 18Transgene (EPA:TNG) Has Debt But No Earnings; Should You Worry?
Nov 24Health Check: How Prudently Does Transgene (EPA:TNG) Use Debt?
Apr 16What Type Of Shareholders Own The Most Number of Transgene SA (EPA:TNG) Shares?
Mar 12Does Transgene's (EPA:TNG) Share Price Gain of 62% Match Its Business Performance?
Jan 23
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2024 | €840k | €600k | -€34m |
| Sep 30 2024 | n/a | n/a | -€28m |
| Jun 30 2024 | n/a | n/a | -€23m |
| Mar 31 2024 | n/a | n/a | -€23m |
| Dec 31 2023 | €510k | €350k | -€22m |
| Sep 30 2023 | n/a | n/a | -€28m |
| Jun 30 2023 | n/a | n/a | -€33m |
| Mar 31 2023 | n/a | n/a | -€33m |
| Dec 31 2022 | €304k | n/a | -€33m |
Compensation vs Market: Alessandro's total compensation ($USD948.19K) is above average for companies of similar size in the French market ($USD303.17K).
Compensation vs Earnings: Alessandro's compensation has increased whilst the company is unprofitable.
CEO
Alessandro Riva (64 yo)
1.9yrs
Tenure
€840,000
Compensation
Dr. Alessandro Riva, M.D., serves as a Director at Bicycle Therapeutics plc since March 25, 2025. He serves as Chairman of the Board and Chief Executive Officer of Transgene SA since June 1, 2023. He serve...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman of the Board | 1.9yrs | €840.00k | 0.022% € 17.8k | |
| VP & Chief Financial Officer | 1.2yrs | no data | no data | |
| Chief Technical Officer | less than a year | no data | no data | |
| Vice President & Chief Scientific Officer | less than a year | no data | no data | |
| VP, General Counsel & Corporate Secretary | 9.2yrs | no data | no data | |
| Chief Human Resources Officer | 1.1yrs | no data | no data | |
| VP & Chief Business Officer | 1.3yrs | no data | no data | |
| VP of Medical Affairs & Chief Medical Officer | less than a year | no data | no data | |
| VP & Director of Human Resources | no data | no data | no data |
1.1yrs
Average Tenure
48yo
Average Age
Experienced Management: TNG's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman of the Board | 3yrs | €840.00k | 0.022% € 17.8k | |
| Director | 25.3yrs | €26.00k | 0.078% € 62.4k | |
| Honorary Chairman | 5.3yrs | no data | 69.3% € 55.4m | |
| Non-Independent Director | 11.9yrs | no data | no data | |
| Director | 20.4yrs | no data | 0.43% € 342.2k | |
| Independent Director | 3yrs | €24.00k | no data | |
| Member of Scientific Advisory Board | 2.2yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 7.9yrs | €48.00k | no data | |
| Independent Director | 2yrs | €45.00k | no data | |
| Independent Director | 7.9yrs | €74.00k | no data | |
| Director | 4.3yrs | no data | no data |
5.3yrs
Average Tenure
64.5yo
Average Age
Experienced Board: TNG's board of directors are considered experienced (5.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/08 19:21 |
| End of Day Share Price | 2025/05/08 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Transgene SA is covered by 8 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Olga Smolentseva | Bryan Garnier & Co |
| Arsene Guekam | CIC Market Solutions (ESN) |
| Michael Thomas Cooper | Edison Investment Research |